

Preventing Type 2 Diabetes Mellitus

Jeff Curtis, MD, MPH, and Charlton Wilson, MD

Type 2 diabetes is a serious, costly, and increasingly common disease. Several conditions commonly seen in family medicine settings confer increased risk of developing diabetes. Among these conditions are impaired glucose tolerance, impaired fasting glucose, obesity, gestational diabetes, hypertension, hyperlipidemia, and menopause. We here present the results of a systematic review of the literature examining the evidence for different strategies aimed at preventing type 2 diabetes in patients with these conditions. The strongest evidence supports an intensive lifestyle intervention designed to induce modest weight loss. The greatest degree of prevention, based on lesser quality evidence, may be imparted by bariatric surgery. Metformin and troglitazone have appreciable evidence in specific populations, and orlistat and acarbose have slightly less evidence among obese patients, for preventing diabetes. Ramipril, captopril, losartan, pravastatin, and estrogens show some very preliminary promise for preventing diabetes in patients treated for hypertension, hyperlipidemia, and menopause, but each needs a more rigorous evaluation. Although more questions remain to be answered, family physicians now have tools available to help our patients lead lives free of diabetes. (J Am Board Fam Pract 2005; 18:37–43.)

Diabetes mellitus is a serious, costly, and increasingly common disease.^{1,2} From the year 2000 to 2050, the number of persons with diagnosed diabetes is projected to increase by 165%.³ The lifetime risk for developing diabetes is estimated to be 32.8% for a man and 38.5% for a woman born in the United States in the year 2000.² The vast majority of these cases will be of type 2 diabetes, a syndrome that is the result of both insulin resistance and insufficient insulin production.⁴ In light of the dramatic epidemic of type 2 diabetes, there is great interest in identifying and implementing interventions to prevent or delay its onset.

Impaired glucose tolerance (IGT) is a condition intermediate between normal glucose homeostasis and type 2 diabetes.⁵ People with IGT are identified by the results of an oral glucose tolerance test with a 2-hour plasma glucose value between 140 and 199 mg/dL. IGT places people at an increased risk of developing type 2 diabetes.⁶ Although not often recognized, as many as 17% of overweight Americans may have the condition.⁷

Like IGT, impaired fasting glucose (IFG) is a condition that falls between normal glucose toler-

ance and diabetes. The diagnostic criterion for IFG is a fasting glucose between 100 and 125 mg/dL.⁸ Both IGT and IFG are associated with an approximately equal risk of diabetes. Those with both IFG and IGT have an even higher risk.⁹ Although it may be tempting to consider IFG as equivalent to IGT, there is very limited information addressing diabetes prevention in patients with IFG only.¹⁰

Other factors that have been shown to increase risk of type 2 diabetes to varying degrees include obesity,^{11,12} a history of gestational diabetes,^{13,14} hypertension,^{15,16} and hyperlipidemia.^{15,16} The risk of diabetes also increases with menopause,^{17–19} and estrogen has known effects on glucose tolerance.²⁰

Using the above risk factors, all of which are conditions commonly confronted in family medicine settings, as potential situations in which prevention may be applied, we present the results of research interventions designed to prevent type 2 diabetes. Although all these interventions are currently available in some form, the United States Food and Drug Administration has not yet approved the medications included in this review for the specific purpose of preventing diabetes.

Methods

Data Sources

We conducted a systematic review of the literature to identify research that addresses the prevention

Submitted, revised, 6 September 2004.

From the Phoenix Indian Medical Center, Indian Health Service, Phoenix, Arizona. Address correspondence to Jeffrey M. Curtis, M.D., M.P.H., Phoenix Indian Medical Center, Indian Health Service, 4212 N. 16th Street, Phoenix, AZ 85016 (e-mail: jfcurtis@mail.nih.gov).




Figure 1. Article selection flow diagram.

of type 2 diabetes. We searched MEDLINE, via PubMed, for reports in English of randomized, controlled trials in humans between January 1, 1965, and January 30, 2004, using the search terms “type 2 diabetes AND prevention,” “NIDDM AND prevention,” and “adult onset diabetes AND prevention.” This search produced a total of 282 articles. We reviewed the titles and abstracts of each study. We also added 5 studies that did not appear in the search but were suggested by subject matter experts or identified during review of the articles. From the combination of these data sources, we identified 18 articles in which preventing type 2 diabetes was the objective. These articles were reviewed in full for confirmation of the primary research outcome, description of the target population and intervention, and identification of the relative and absolute risk reduction of the intervention (Figure 1).

Results

People with Impaired Glucose Tolerance

The Diabetes Prevention Program (DPP) studied people with IGT.²¹ This study’s intervention included structured education, individualized medical nutrition therapy, and intensive lifestyle modification and support designed to result in 150 minutes of physical activity per week and a 7% weight loss. Participants in the control group were given information on healthy eating patterns and exercise, but

they did not receive intensive lifestyle support. The absolute risk of developing diabetes in the intervention group was 4.8% per year, compared with 11.0% per year in the control group. Using the DPP intervention, 7 people with IGT would need to be treated for 1 year to prevent 1 new case of diabetes [the number needed to treat (NNT) per year is 7]. Similar results were seen in the Finnish Diabetes Prevention Study (DPS).²² In the DPS, a comparable lifestyle adaptation intervention also resulted in 3.2% of patients in the intervention group developing diabetes, compared with 7.8% in the control group, for an NNT of 5 people with IGT over 5 years. Several other smaller studies have confirmed that similar lifestyle interventions can reduce the risk of type 2 diabetes.^{23–26}

In another arm of the DPP, metformin (Glucophage) at a dose of 850 mg twice daily was compared with a placebo. The incidence of diabetes in the treated patients was 7.8%, compared with 11.0% in the placebo group. Twenty patients with IGT needed to be treated with metformin for 3 years to prevent 1 new case of diabetes. It is noteworthy that metformin was not more effective than placebo among those patients with a body mass index (BMI: weight in kilograms divided by square of height in meters) less than 30 kg/m², among those over 60 years old, or in those whose fasting plasma glucose was less than 110 mg/dL. The com-

bination of metformin and lifestyle intervention was not studied.

The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) examined the ability of the α -glucosidase inhibitor acarbose (Precose) to prevent type 2 diabetes in overweight and obese patients with IGT.²⁷ In this study, patients treated with acarbose, at a dose up to 100 mg 3 times daily, experienced a diabetes incidence of 17% over 3.3 years, whereas the placebo group's diabetes incidence was 26%. The NNT in this study was 11.5 patients treated for 3.3 years. The benefit of acarbose was seen across the range of age and obesity included in the study.

The weight loss medication orlistat (Xenical), a gastrointestinal lipase inhibitor, may also be effective in people with IGT. In a recent study of 3305 obese (BMI ≥ 30 kg/m²) patients with IGT, those treated with orlistat 120 mg 3 times daily experienced a 6.2% incidence of diabetes over 4 years, whereas those treated with placebo had a 9.0% incidence.²⁸ Ten patients would need to be treated with orlistat for 4 years to prevent 1 new case of diabetes. In a meta-analysis from 3 weight loss studies that used orlistat in the same dose as above, obese (BMI ≥ 30 kg/m²) patients with IGT who were treated with orlistat experienced a 3.0% incidence of diabetes, compared with a 7.6% incidence in those treated with placebo.²⁹ According to this meta-analysis, 45 obese patients with IGT would need to be treated for 2 years to prevent 1 new case of diabetes.

Other medications have been evaluated in small studies or will be evaluated soon to determine their ability to prevent diabetes in patients with IGT or similar risk.^{30,31}

Obese People with Normal Glucose Tolerance

In the same meta-analysis cited above, among 522 obese people (BMI 30–43 kg/m²) with normal glucose tolerance, 120 mg of orlistat 3 times daily resulted in a decreased incidence of diabetes.²⁹ Those randomized to placebo experienced a 10.8% incidence of IGT and a 1.2% incidence of diabetes over a 2-year period, whereas those who received orlistat had a 6.6% incidence of IGT and none developed diabetes. The apparent relative risk reduction for diabetes incidence over the course of this short study was 100%, but interpretation is complicated by the low incidence of diabetes in the placebo group.

In the Swedish Obese Subjects (SOS) Study, obese (BMI ≥ 34 kg/m² for men or ≥ 38 kg/m² for women) patients treated with gastrointestinal surgery to promote weight loss are compared with matched (but not randomized) nonsurgically treated control patients.^{32,33} Surgically treated patients have shown reductions of up to 97% in diabetes incidence at 2 and 5 years after surgery. The risk reduction has been greatest among those whose weight loss has been greatest. The observational nature of the study limits the ability to generalize the findings. Liposuction does not seem to affect glucose metabolism.³⁴

Women with Previous Gestational Diabetes

The Troglitazone in Prevention of Diabetes (TRIPOD) trial studied Hispanic women with a history of gestational diabetes.³⁵ Women with 2-hour oral glucose tolerance test values in the high end of the normal range were randomized to receive the thiazolidinedione troglitazone (Rezulin) in a dose of 400 mg daily or placebo. The treated group experienced an annual diabetes incidence of 5.4% compared with 12.1% in the placebo group. The NNT was 15 patients for 1 year. Troglitazone has since been removed from the market because of an increased risk of hepatotoxicity. Currently available thiazolidinediones do not seem to share as high a risk of hepatotoxicity but have not been studied for the purpose of preventing diabetes.³⁶

People with Hyperlipidemia or Hypertension

Several large cardiovascular disease prevention studies have recently published post hoc analyses of the incidence of diabetes among subgroups of participants. Among people with a history of coronary artery disease, the angiotensin-converting enzyme inhibitor ramipril (Altace), up to 10 mg daily, was associated with a decrease in incidence of diabetes from 5.4% over 4.5 years in the placebo group to 3.6% in the treated group (NNT = 56 for 4.5 years).³⁷ Use of another angiotensin-converting enzyme inhibitor, captopril (Capoten), titrated to keep supine diastolic blood pressure below 90 mm Hg, was associated with diabetes incidence of 13.3%, compared with 15.2% over 5 years in those treated with diuretics and β -adrenergic receptor blockers for hypertension (NNT = 53 over 5 years).³⁸ Likewise, the angiotensin receptor blocker losartan (Cozaar), titrated to keep blood pressure below 140/90 mm Hg, was associated with a 1.30%

Table 1. Recent Major Diabetes Prevention Studies

Study (year)	Population	N	Design	Intervention	RR ↓ vs. placebo	Absolute Risk Placebo Group (Intervention Group)	NNT/Time
Da Qing (1997) ²⁴	Over 25 years IGT	577	Randomized (by clinic) controlled trial	Diet and Exercise	42%	15.7% per year (9.6% per year)	16.4/6 years
DPS (2001) ²²	40–65 years BMI ≥25 kg/m ² IGT	522	Randomized controlled trial	Diet and Exercise	58%	7.8% per year (3.2% per year)	22/year or 5/5 years
DPP (lifestyle) (2002) ²¹	≥25 years BMI ≥24 kg/m ² IGT	3234	Randomized controlled trial	Diet and Exercise	58%	11.0% per year (4.8% per year)	6.9/3 years
DPP (metformin) (2002) ²¹	≥25 years BMI ≥24 kg/m ² IGT	3234	Randomized controlled trial	Metformin	31%	11.0% per year (7.8% per year)	13.9/3 years
TRIPOD (2002) ^{3,5}	Hispanic nondiabetic women with history of gestational diabetes	235	Randomized controlled trial	Troglitazone	56%	12.1% per year (5.4% per year)	15/year
STOP-NIDDM (2002) ²⁷	40–70 years BMI 25–40 kg/m ² IGT FPG 100–140 mg/dL	1429	Randomized controlled trial	Acarbose	25–36%	26% over 3.3 years (17% over 3.3 years)	11.5/3.3 years
XENDOS (2004) ²⁸	BMI ≥30 kg/m ² 30–60 years	3305	Randomized controlled trial	Orlistat	33.7%	9.0% over 4 years (6.2% over 4 years)	36/4 years (10/4 years with IGT)
SOS (1999) ³²	37–60 years BMI ≥38 (women) or BMI ≥34 kg/m ² (men)	1690	Case-control study	Bariatric surgery	97%	6.3% over 2 years (0.2% over 2 years)	16/2 years

incidence of diabetes per year, compared with 1.75% per year in patients treated with the β -adrenergic receptor blocker atenolol (Tenormin) for hypertension and left ventricular hypertrophy (NNT = 222 per year).³⁹ In men with hyperlipidemia, use of pravastatin (Pravachol), at a dose of 40 mg daily, was associated with a 1.9% incidence of diabetes over 5.5 years compared with 2.8% in those patients treated with placebo (NNT = 111 for 5.5 years).⁴⁰ It is not known whether other medications in these classes will have similar effects or whether these findings will withstand the scrutiny of a randomized clinical trial.

Women after Menopause

In postmenopausal women, hormone replacement therapy, using 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (Prempro) daily, was associated with a 6% incidence of diabetes over 4.1 years, versus 10% in patients treated with placebo.⁴¹ In this study, 30 postmenopausal women needed to be treated for 4.1 years to prevent 1 new case of diabetes. Any potential diabetes prevention benefits of hormone replacement therapy will need to be balanced against the other complicated risks of the therapy.

These studies are summarized in Table 1, and strength of recommendation data are provided in Table 2.

Discussion

Amid all the attention given to the increasing incidence of type 2 diabetes, there is also ever-mounting evidence that the disease is preventable, even

among those at highest risk. The preventive strategy with the best supporting evidence is an intensive lifestyle intervention, designed to produce modest weight loss. Although on face value the success of the DPP and the DPS may tempt physicians to recommend healthy eating and regular exercise, using the specific intervention strategies as the basis for a discussion with patients, and to believe therefore that they have provided an evidence-based preventive intervention, it is important to realize that even the control groups in these studies received more intervention than routine physician recommendations. The interventions were intensive, interdisciplinary, individualized programs aimed at inducing weight loss. Truly implementing a version of these interventions will require developing treatment teams with the ability to motivate patients to make changes in lifestyle patterns that have probably been present for decades.

The intervention that seems (based on lesser quality evidence) to have the greatest potential for preventing diabetes is bariatric surgery. However, this treatment is far more invasive than the lifestyle interventions, and the surgery requires lifestyle modifications that are probably more intensive. Because of its cost and invasiveness, bariatric surgery will probably never be the diabetes prevention strategy of choice for the majority of the at-risk population.

The medications with the strongest evidence supporting their ability to prevent diabetes are metformin and troglitazone. Of course, troglitazone is no longer available, and whether other thiazo-

Table 2. Evidence

Key Clinical Recommendation	Strength of Recommendation	Reference(s)	Comment and References
A lifestyle intervention aimed at inducing 5%–7% weight loss can prevent type 2 diabetes in patients with IGT	A	8, 9	Recommendation based on two large randomized clinical trials. References 10–13 are less powerful but supporting.
Metformin can help to prevent type 2 diabetes, especially in younger, more obese patients with IGT	B	8	Recommendation based on one large randomized clinical trial.
Acarbose can help to prevent type 2 diabetes in patients with IGT	B	14	Recommendation based on one randomized clinical trial.
Orlistat can help to prevent type 2 diabetes in obese patients with IGT	B	15, 16	Recommendation based on one randomized clinical trial and one meta-analysis of three other clinical trials.

For further explanation of strength of recommendation, see Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *J Am Board Fam Pract* 2004;17:59–67.

lidediones will have similar benefits is yet to be seen. Orlistat and acarbose also show considerable promise. The other medications included in this review (ramipril, captopril, losartan, pravastatin, and estrogens) have been evaluated only in post hoc subgroup analyses. Therefore, they do not carry nearly the weight of evidence for preventing diabetes that metformin, orlistat, and acarbose do.

It is clear that there is much yet to learn about preventing type 2 diabetes. For example, does the combination of lifestyle intervention and medication have a greater effect than either alone? Does preventing diabetes by these strategies also prevent the micro- and macrovascular complications of diabetes, or does it merely prevent glucose elevation above diagnostic values? And can earlier intervention among patients with familial risk but no aberration in glucose homeostasis prevent diabetes more effectively than intervention after other risk factors have become apparent? However, there is sufficient evidence that diabetes can be prevented using techniques and agents that are currently available. The onus is now on us as physicians to implement this evidence to help our patients improve their chances of leading lives free of this disease.

References

- Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. *Diabetes Care* 2003;26:917–32.
- Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. *JAMA* 2003;290:1884–90.
- Boyle JP, Honeycutt AA, Narayan KMV, et al. Projection of diabetes burden through 2050. *Diabetes Care* 2001;24:1936–40.
- Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 1999;104:787–94.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2004;27 Suppl 1:5–10.
- Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization Criteria for Hyperglycemia in the diagnosis and prediction of diabetes. *Diabetes Care* 2000;23:1108–12.
- Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KMV. Estimated number of adults with prediabetes in the U.S. in 2000. *Diabetes Care* 2003;26:645–9.
- Genuth S, Alberti KG, Bennett P, et al., and Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003;26:3160–7.
- de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. *JAMA* 2001;285:2109–13.
- Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR. The fasting hyperglycaemia study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. *Metabolism* 1997;46(12 Suppl 1):56–60.
- Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. *N Engl J Med* 2001;345:790–7.
- Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA* 1999;282:1523–9.
- Jovanovic L, Pettit DJ. Gestational diabetes mellitus. *JAMA* 2001;286:2516–8.
- Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care* 2002;25:1862–8.
- American Diabetes Association. Screening for type 2 diabetes. *Diabetes Care* 2004;27 Suppl 1:S11–4.
- American Diabetes Association. Prevention or delay of type 2 diabetes. *Diabetes Care* 2004;27 Suppl 1:S47–54.
- Liu P, Li Y, Yu H. Relationship between diabetes mellitus, impaired glucose tolerance and age, menopause, pregnancy: a survey of 5153 women in Shenzhen. *Chin Med J (Engl)* 1999;112:612–4.
- Wu SI, Chou P, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. *J Clin Epidemiol* 2001;54:117–20.
- Gaspard UJ, Gottal JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. *Maturitas* 1995;21:171–8.
- Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. *Diabetes Care* 1998;21:1589–95.
- Knowler WC, Barrett-Connor E, Fowler SE, et al., and Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
- Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–50.
- Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991;34:891–8.

24. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. *Diabetes Care* 1997;20:537–44.
25. Mensink M, Feskens EJ, Saris WH, De Bruin TW, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. *Int J Obes Relat Metab Disord* 2003;27:377–84.
26. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5 year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. *Diabetes Care* 2001;24:619–24.
27. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;359:2072–7.
28. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27:155–61.
29. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. *Arch Intern Med* 2000;160:1321–6.
30. Saloranta C, Buitard C, Pecher E, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. *Diabetes Care* 2002;25:2141–6.
31. Schuster D, Gaillard T, Rhinsmith S, Habash D, Osei K. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus; a placebo-controlled, 24-month randomized study. *Metabolism* 2003;52:1211–7.
32. Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. *Obes Res* 1999;7:477–84.
33. Torgerson JS, Sjöström L. The Swedish obese subjects (SOS) study—rationale and results. *Int J Obes Relat Metab Disord* 2001;25 Suppl 1:S2–4.
34. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. *N Engl J Med* 2004;350:2549–57.
35. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. *Diabetes* 2002;51:2796–803.
36. Scheen AJ. Thiazolidinediones and liver toxicity. *Diabetes Metab* 2001;27:1350–4.
37. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. *JAMA* 2001;286:1882–5.
38. Captopril Prevention Project study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet* 1999;353:611–6.
39. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. *J Hypertension* 2002;20:1879–86.
40. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 2001;103:357–62.
41. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the estrogen/progestin replacement study. *Ann Intern Med* 2003;139:1–9.